[Use of crizotinib for refractory ALK-positive lymphomas].
| Autor: | Shelikhova LN; Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia., Fominykh VV; Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia., Abramov DS; Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia., Myakova NV; Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia., Maschan MA; Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia., Maschan AA; Dmitry Rogachev Federal Research and Practical Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Health of Russia, Moscow, Russia. |
|---|---|
| Jazyk: | ruština |
| Zdroj: | Terapevticheskii arkhiv [Ter Arkh] 2017; Vol. 89 (7), pp. 51-56. |
| DOI: | 10.17116/terarkh201789751-56 |
| Abstrakt: | Aim: To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). Subjects and Methods: The paper describes the experience with crizotinib used in 8 patients with refractory ALK-ALCL before and after allogeneic hematopoietic stem cell transplantation (HSCT). Results: All the 8 (100%) patients treated with crizotinib were recorded to have complete responses, including complete metabolic ones (tumor disappearance as evidenced by positron emission tomography (PET)/computed tomography. Conclusion: Low and manageable toxicity of crizotinib and complete PET-negative responses in patients with resistant ALK lymphomas favor the need to test the drug as first-line therapy, by possibly decreasing the intensification of chemotherapy. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|